Between July 2012 and April 2014 we randomly assigned 30 high-risk patientsto undergo transaortic TAVI with the SAPIEN XT prosthesis ( Edwards Lifesciences ) combined with either the EMBOL-X device ( group-1 , n = 14 ) or without ( group-2 , n = 16 ) .